1. All Articles

    1-24 of 3152 1 2 3 4 ... 130 131 132 »
    1. Desogestrel DOWN-REGULATES PHOX2B And Its Target Genes In Progesterone Responsive Neuroblastoma Cells.

      DESOGESTREL DOWN-REGULATES PHOX2B AND ITS TARGET GENES IN PROGESTERONE RESPONSIVE NEUROBLASTOMA CELLS.

      Exp Cell Res. 2018 Jul 20;:

      Authors: Cardani S, Di Lascio S, Belperio D, Di Biase E, Ceccherini I, Benfante R, Fornasari D

      Abstract The paired-like homeobox 2B gene (PHOX2B) encodes a key transcription factor that plays a role in the development of the autonomic nervous system and the neural structures involved in controlling breathing.

      Read Full Article
      Mentions: PHOX2B
    2. GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells.

      GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells.

      Apoptosis. 2018 Jul 19;:

      Authors: Durbas M, Pabisz P, Wawak K, Wiśniewska A, Boratyn E, Nowak I, Horwacik I, Woźnicka O, Rokita H

      Read Full Article
      Mentions: Antibody
    3. Long term outcomes after concurrent ipsilateral nephrectomy versus kidney-sparing surgery for high-risk, intraabdominal neuroblastoma.

      Long term outcomes after concurrent ipsilateral nephrectomy versus kidney-sparing surgery for high-risk, intraabdominal neuroblastoma.

      J Pediatr Surg. 2018 Jul 06;:

      Authors: Fahy AS, Roberts A, Nasr A, Irwin MS, Gerstle JT

      Abstract PURPOSE: The impact of the extent of surgical resection including nephrectomy for high-risk neuroblastoma patients is controversial.

      Read Full Article
      Mentions: Surgery
    4. Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma.

      Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma.

      Proc Natl Acad Sci U S A. 2018 Jul 18;:

      Authors: Kerosuo L, Neppala P, Hsin J, Mohlin S, Vieceli FM, Török Z, Laine A, Westermarck J, Bronner ME

      Read Full Article
      Mentions: MYCN
    5. Parental perception of child vulnerability in childhood cancer survivors.

      Parental perception of child vulnerability in childhood cancer survivors.

      Pediatr Blood Cancer. 2018 Jul 19;:e27364

      Authors: Staba Hogan MJ, Ross WL, Balsamo L, Mitchell HR, Kadan-Lottick NS

      Abstract BACKGROUND: Parents' perception of their children's vulnerability to illness following cancer treatment is largely unknown, but is important to understand given known challenges of transitioning survivors to postcancer care.

      Read Full Article
      Mentions: Treatment
    6. Exercise linked to reduced mortality in survivors of childhood cancer

      Exercise linked to reduced mortality in survivors of childhood cancer

      1. In this retrospective cohort analysis, adult survivors of childhood cancer demonstrated reduced mortality with increasing levels of vigorous exercise in a week. 2. Increasing the degree of vigorous exercise was also linked to a reduction in mortality compared to maintaining activity levels. Evidence Rating Level: 3 (Average)       Study Rundown: Adult survivors of childhood cancer []

      Read Full Article
    7. In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      J Control Release. 2018 Jul 03;285:162-171

      Authors: Yavuz B, Zeki J, Coburn JM, Ikegaki N, Levitin D, Kaplan DL, Chiu B

      Abstract High-risk neuroblastoma requires surgical resection and multi-drug chemotherapy. This study aimed to develop an extended release, implantable and degradable delivery system for etoposide, commonly used for neuroblastoma treatment.

      Read Full Article
    8. An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma.

      An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma.

      Oncotarget. 2018 Jun 26;9(49):29082-29096

      Authors: Tesson M, Vasan R, Hock A, Nixon C, Rae C, Gaze M, Mairs R

      Abstract Targeted radiotherapy of metastatic neuroblastoma using the somatostatin receptor (SSTR)-targeted octreotide analogue DOTATATE radiolabelled with lutetium-177 (177Lu-DOTATATE) is a promising strategy.

      Read Full Article
    9. Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.

      Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.

      Biol Direct. 2018 Jul 16;13(1):14

      Authors: Suo C, Deng W, Vu TN, Li M, Shi L, Pawitan Y

      Abstract BACKGROUND: Neuroblastoma is the most common pediatric malignancy with heterogeneous clinical behaviors, ranging from spontaneous regression to aggressive progression.

      Read Full Article
      Mentions: MYCN
    10. Correlation of CT signs with lymphatic metastasis and pathology of neuroblastoma in children.

      Correlation of CT signs with lymphatic metastasis and pathology of neuroblastoma in children.

      Oncol Lett. 2018 Aug;16(2):2439-2443

      Authors: Zhang X, Li C, Xu C, Hao X, Yu X, Li Q

      Abstract Correlation between computed tomography (CT) signs, lymphatic metastasis and pathological features of neuroblastoma (NB) in children was investigated.

      Read Full Article
      Mentions: Metastasis
    11. Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study

      Risk stratification is crucial to treatment decision‐making in neuroblastoma. This study aimed to explore factors present at diagnosis affecting outcome in patients aged ≥18 months with metastatic neuroblastoma and to develop a simple risk score for prognostication.

      Read Full Article
      Mentions: Treatment SIOPEN MYCN
    12. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.

      Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.

      Pediatr Blood Cancer. 2018 Jul 14;:e27354

      Authors: Druy AE, Shorikov EV, Tsaur GA, Popov AM, Zaychikov AN, Tuponogov SN, Saveliev LI, Tytgat GAM, Fechina LG

      Read Full Article
      Mentions: Bone Marrow PHOX2B
    13. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR

      Expression of PHOX2B , TH , ELAVL4 , and B4GALNT1 (GD2‐synthase) was analyzed by quantitative polymerase chain reaction in neuroblastoma cell lines, control BM samples, and in BM samples from patients. The threshold level of expression for each gene was established through receiver operator characteristic analysis and used to determine the diagnostic test performance. The prognostic significance of BM involvement was assessed by survival rates calculations.

      Read Full Article
      Mentions: Bone Marrow PHOX2B
    14. Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase.

      Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase.

      Molecules. 2018 Jul 02;23(7):

      Authors: Jiang CH, Huang CX, Chen YJ, Chuang YC, Huang BY, Yang CN

      Abstract Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in various cancers. In its basal state, the structure of ALK is in an autoinhibitory form stabilized by its A-loop, which runs from the N-lobe to the C-lobe of the kinase.

      Read Full Article
      Mentions: ALK
    15. Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

      Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

      Conditions :   Childhood Solid Tumor;   Childhood Lymphoma Interventions :   Drug: Vinblastine;   Drug: Cyclophosphamide;   Drug: Capecitabine;   Drug: Nivolumab Sponsors :   Centre Oscar Lambret;   Anticancer Fund, Belgium;   Bristol-Myers Squibb Not yet recruiting

      Read Full Article
    16. Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.

      Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.

      Asia Ocean J Nucl Med Biol. 2018;6(2):161-166

      Authors: Araki R, Nishimura R, Inaki A, Wakabayashi H, Imai Y, Kuribayashi Y, Yoshimura K, Murayama T, Kinuya S

      Read Full Article
      Mentions: MIBG Chemotherapy
    17. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

      Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

      Br J Cancer. 2018 Jul 11;:

      Authors: Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T

      Read Full Article
      Mentions: GPOH Chemotherapy
    18. Somatic mutations in specific and connected sub-pathways are associated to short neuroblastoma patients' survival and indicate proteins targetable at onset of disease.

      Somatic mutations in specific and connected sub-pathways are associated to short neuroblastoma patients' survival and indicate proteins targetable at onset of disease.

      Int J Cancer. 2018 Jul 11;:

      Authors: Esposito MR, Binatti A, Pantile M, Coppe A, Mazzocco K, Longo L, Capasso M, Lasorsa VA, Luksch R, Bortoluzzi S, Tonini GP

      Read Full Article
    19. Clinical And Epidemiological Characteristics And Survival Outcomes Of Children With Neuroblastoma: 21 Years Of Experience At The Instituto De Oncologia PediÁtrica, In SÃo Paulo, Brazil.

      CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS AND SURVIVAL OUTCOMES OF CHILDREN WITH NEUROBLASTOMA: 21 YEARS OF EXPERIENCE AT THE INSTITUTO DE ONCOLOGIA PEDIÁTRICA, IN SÃO PAULO, BRAZIL.

      Rev Paul Pediatr. 2018 Jul 10;:

      Authors: Lucena JN, Alves MTS, Abib SCV, Souza GO, Neves RPC, Caran EMM

      Read Full Article
    20. EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, Qarziba®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma

      EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, Qarziba®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma

      HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--EUSA Pharma today welcomed a decision by the National Institute for Health and Care Excellence (NICE) to recommend the use of the targeted cancer immunotherapy, QARZIBA® (dinutuximab beta) to treat children with high-risk neuroblastoma within the NHS in England and Wales.i High-risk neuroblastoma is an aggressive form of neuroblastoma – the most common solid tumour of childhood that originates outside of the brain.ii Dinutuximab beta is the first targe

      Read Full Article
    1-24 of 3152 1 2 3 4 ... 130 131 132 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. INBRACED

    See all INBRACED articles
  4. Organizations in the News

    1. (89 articles) COG
    2. (27 articles) NANT
    3. (25 articles) SIOPEN
    4. (23 articles) SIOP
    5. (18 articles) MSKCC
    6. (17 articles) GPOH
    7. (16 articles) INRG
    8. (11 articles) NMTRC
  5. Locations in the News

    1. (9 articles) Other Countries
  6. Researches in the News

    1. (302 articles) MYCN
    2. (227 articles) Immunotherapy
    3. (146 articles) Antibody
    4. (129 articles) ALK
    5. (95 articles) Imaging
    6. (76 articles) T-Cells
    7. (67 articles) Bone Marrow
    8. (55 articles) Metastasis
    9. (49 articles) ASCO
    10. (36 articles) Genetics
  7. General Informations in the News

    1. (464 articles) Treatment
    2. (24 articles) Staging
    3. (7 articles) Hearing Loss
  8. Treatments in the News

    1. (111 articles) Surgery
    2. (109 articles) Chemotherapy
    3. (101 articles) Refractory
    4. (90 articles) MIBG
    5. (73 articles) Relapse
    6. (69 articles) Stem Cell Transplant
    7. (66 articles) Radiotherapy
    8. (26 articles) Side Effects
    9. (21 articles) Diagnostics
    10. (9 articles) Targetted Therapy